Dr Robert Zimmerman Discusses Challenges, Adverse Effects of GLP-1 and Multi-Agonist Therapies
Robert Zimmerman, MD, discussed the adverse side effects associated with glucagon-like peptide-1 (GLP1) and multi-agonist therapies, as well as explored the challenges in developing these interventions.